Prostate HIFU lands in the U.S. Now what? "With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD. New discoveries, treatments help cancer patients live longer, fuller lives Experts say that value-based medicine is a main theme in cancer care today, and that applies to more than the cost of care. Prostate biopsy-related infections raise transfusion risk May 08, 2016 By Mac Overmyer Paradoxically, the authors of a large study did not find a negative effect in functional outcomes analyzed. Data offer new insight on HIFU’s use in low-risk PCa May 07, 2016 By Randy Dotinga Transrectal HIFU shows a statistically significant increase in per-core negative biopsy rates. Use of observation for PCa varies widely among urologists A CMS quality measure needs to be bidirectional, “specifying a rate of observation for low-risk disease and a rate of treatment for high-risk disease,” researchers say. Peri-op transfusion raises short-term morbidity risk A retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database. Study finds prostate Ca clones trackable by fusion biopsy Specific clones may have the potential for grade conversion, research suggests. AS success rate strong in appropriate PCa patients May 06, 2016 By Wayne Kuznar Large study examines surveillance results in men with very low-, low-, intermediate-, and high-risk disease. Greater long-term side effect risk with intermittent ADT May 01, 2016 By Wayne Kuznar In men with metastatic prostate cancer, those assigned to intermittent androgen deprivation therapy have more ischemic and thrombotic events than those assigned to continuous androgen deprivation, according to Columbia University researchers. No link between PDE-5 use, prostate Ca recurrence May 01, 2016 By Wayne Kuznar No significant relationship was found between use of a phosphodiesterase type-5 inhibitor and prostate cancer recurrence after treatment in a nested case-control study.